Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A bridging HSCT in r/r B-ALL
NCT05576181Phase 1Unknown
- Sponsor
- Fundamenta Therapeutics Inc.
- Start
- Oct 2022
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Fundamenta Therapeutics Inc. Primary endpoints: Dose Limited Toxicity at 28 days and Overall Complete Response Rate at 3 months. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05576181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576181.